These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9047384)

  • 41. Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase.
    Scott RP; Eketjäll S; Aineskog H; Ibáñez CF
    J Biol Chem; 2005 Apr; 280(14):13442-9. PubMed ID: 15677445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins.
    Qiao S; Iwashita T; Furukawa T; Yamamoto M; Sobue G; Takahashi M
    J Biol Chem; 2001 Mar; 276(12):9460-7. PubMed ID: 11121408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
    Iervolino A; Iuliano R; Trapasso F; Viglietto G; Melillo RM; Carlomagno F; Santoro M; Fusco A
    Cancer Res; 2006 Jun; 66(12):6280-7. PubMed ID: 16778204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
    Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
    Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
    Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
    Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
    Carlomagno F; De Vita G; Berlingieri MT; de Franciscis V; Melillo RM; Colantuoni V; Kraus MH; Di Fiore PP; Fusco A; Santoro M
    EMBO J; 1996 Jun; 15(11):2717-25. PubMed ID: 8654369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells.
    Warner AJ; Lopez-Dee J; Knight EL; Feramisco JR; Prigent SA
    Biochem J; 2000 Apr; 347(Pt 2):501-9. PubMed ID: 10749680
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas.
    Lanzi C; Borrello MG; Bongarzone I; Migliazza A; Fusco A; Grieco M; Santoro M; Gambetta RA; Zunino F; Della Porta G
    Oncogene; 1992 Nov; 7(11):2189-94. PubMed ID: 1437145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tyrosine-614, the major autophosphorylation site of the receptor tyrosine kinase HEK2, functions as multi-docking site for SH2-domain mediated interactions.
    Hock B; Böhme B; Karn T; Feller S; Rübsamen-Waigmann H; Strebhardt K
    Oncogene; 1998 Jul; 17(2):255-60. PubMed ID: 9674711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gads is a novel SH2 and SH3 domain-containing adaptor protein that binds to tyrosine-phosphorylated Shc.
    Liu SK; McGlade CJ
    Oncogene; 1998 Dec; 17(24):3073-82. PubMed ID: 9872323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
    Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ; Ponder BA; Hancock JF
    Cancer Res; 1997 Dec; 57(23):5399-405. PubMed ID: 9393766
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
    Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
    Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
    Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
    J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
    Hofstra RM; van der Luijt RB; Lips CJ
    Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MEN2A-RET-induced cellular transformation by activation of STAT3.
    Schuringa JJ; Wojtachnio K; Hagens W; Vellenga E; Buys CH; Hofstra R; Kruijer W
    Oncogene; 2001 Aug; 20(38):5350-8. PubMed ID: 11536047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain.
    O'Bryan JP; Songyang Z; Cantley L; Der CJ; Pawson T
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2729-34. PubMed ID: 8610109
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching.
    Degl'Innocenti D; Arighi E; Popsueva A; Sangregorio R; Alberti L; Rizzetti MG; Ferrario C; Sariola H; Pierotti MA; Borrello MG
    Oncogene; 2004 Sep; 23(44):7297-309. PubMed ID: 15326489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.
    Bongarzone I; Vigano E; Alberti L; Borrello MG; Pasini B; Greco A; Mondellini P; Smith DP; Ponder BA; Romeo G; Pierotti MA
    Oncogene; 1998 May; 16(18):2295-301. PubMed ID: 9620546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation.
    Kato M; Iwashita T; Akhand AA; Liu W; Takeda K; Takeuchi K; Yoshihara M; Hossain K; Wu J; Du J; Oh C; Kawamoto Y; Suzuki H; Takahashi M; Nakashima I
    Antioxid Redox Signal; 2000; 2(4):841-9. PubMed ID: 11213488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.